Mr. Mackison was appointed CEO of Vico Therapeutics in August 2022. Mr. Mackison joined from Locanabio, an RNA-targeted gene therapy company where he was Chief Business Officer and Executive Vice President of Strategy and Corporate Development. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, he was Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S focused on neuroscience. Prior to the acquisition by Lundbeck, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s Disease.
Previously, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.